NCT02761187 · OUTCOME

Number of Treatment Sequencing

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants · Source last updated 2025-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Baseline up to 5 years

What was measured

Drug classes were based on the earliest regimen in each corresponding Line of Therapy. The data for this outcome measure was analyzed as per line of therapy.

Analysis population: All Enrolled Population included all participants who signed informed consent. Participants were reported more than once in each line of therapy. Data is reported only for 1st, 2nd and 3rd line of therapy.

Groups in this outcome

1st Line of Therapy

The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).

2nd Line of Therapy

The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).

3rd Line of Therapy

The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
1st Line of Therapy	4224
2nd Line of Therapy	2748
3rd Line of Therapy	1734

Reported measurements

mAB based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	41	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	77	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	129	Not reported	Not reported	Not reported	Not reported

mAB/IMID based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	290	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	213	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	128	Not reported	Not reported	Not reported	Not reported

mAB/PI based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	156	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	119	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	69	Not reported	Not reported	Not reported	Not reported

mAB/alkalytor based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	2	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	7	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	6	Not reported	Not reported	Not reported	Not reported

mAB/IMID/PI based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	36	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	14	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	12	Not reported	Not reported	Not reported	Not reported

Cytotoxic

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	74	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	59	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	49	Not reported	Not reported	Not reported	Not reported

IMID based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	515	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	361	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	118	Not reported	Not reported	Not reported	Not reported

PI based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	366	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	204	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	101	Not reported	Not reported	Not reported	Not reported

Alkylator based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	79	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	40	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	33	Not reported	Not reported	Not reported	Not reported

PI/IMID based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	608	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	295	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	115	Not reported	Not reported	Not reported	Not reported

PI/alkylator based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	351	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	137	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	57	Not reported	Not reported	Not reported	Not reported

IMID/alkylator based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	123	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	119	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	57	Not reported	Not reported	Not reported	Not reported

PI/IMID/alkylator based

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	34	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	14	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	7	Not reported	Not reported	Not reported	Not reported

Other

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	59	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	32	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	46	Not reported	Not reported	Not reported	Not reported

Unknown

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
1st Line of Therapy	1490	Not reported	Not reported	Not reported	Not reported
2nd Line of Therapy	1057	Not reported	Not reported	Not reported	Not reported
3rd Line of Therapy	807	Not reported	Not reported	Not reported	Not reported

Complete source fields

calculate Pct

false

classes

categories
measurements
group Id
OG000
value
41
group Id
OG001
value
77
group Id
OG002
value
129
title
mAB based
categories
measurements
group Id
OG000
value
290
group Id
OG001
value
213
group Id
OG002
value
128
title
mAB/IMID based
categories
measurements
group Id
OG000
value
156
group Id
OG001
value
119
group Id
OG002
value
69
title
mAB/PI based
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
7
group Id
OG002
value
6
title
mAB/alkalytor based
categories
measurements
group Id
OG000
value
36
group Id
OG001
value
14
group Id
OG002
value
12
title
mAB/IMID/PI based
categories
measurements
group Id
OG000
value
74
group Id
OG001
value
59
group Id
OG002
value
49
title
Cytotoxic
categories
measurements
group Id
OG000
value
515
group Id
OG001
value
361
group Id
OG002
value
118
title
IMID based
categories
measurements
group Id
OG000
value
366
group Id
OG001
value
204
group Id
OG002
value
101
title
PI based
categories
measurements
group Id
OG000
value
79
group Id
OG001
value
40
group Id
OG002
value
33
title
Alkylator based
categories
measurements
group Id
OG000
value
608
group Id
OG001
value
295
group Id
OG002
value
115
title
PI/IMID based
categories
measurements
group Id
OG000
value
351
group Id
OG001
value
137
group Id
OG002
value
57
title
PI/alkylator based
categories
measurements
group Id
OG000
value
123
group Id
OG001
value
119
group Id
OG002
value
57
title
IMID/alkylator based

denoms

counts
group Id
OG000
value
4224
group Id
OG001
value
2748
group Id
OG002
value
1734
units
Participants

description

Drug classes were based on the earliest regimen in each corresponding Line of Therapy. The data for this outcome measure was analyzed as per line of therapy.

groups

description
The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
id
OG000
title
1st Line of Therapy
description
The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
id
OG001
title
2nd Line of Therapy
description
The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).
id
OG002
title
3rd Line of Therapy

param Type

COUNT_OF_PARTICIPANTS

population Description

All Enrolled Population included all participants who signed informed consent. Participants were reported more than once in each line of therapy. Data is reported only for 1st, 2nd and 3rd line of therapy.

reporting Status

POSTED

time Frame

Baseline up to 5 years

title

Number of Treatment Sequencing

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice